Senores Pharmaceuticals Limited (BOM:544319)
India · Delayed Price · Currency is INR 1,387.20
+64.50 (4.88%)
At close: Oct 6, 2026
Senores Pharmaceuticals Revenue
Senores Pharmaceuticals had revenue of 1.80B INR in the quarter ending June 30, 2026, with 38.30% growth. This brings the company's revenue in the last twelve months to 6.80B, up 51.49% year-over-year. In the fiscal year ending March 31, 2026, Senores Pharmaceuticals had annual revenue of 6.33B with 58.85% growth.
Revenue (ttm)
6.80B
Revenue Growth
+51.49%
P/S Ratio
9.40
Revenue / Employee
18.49M
Employees
368
Market Cap
63.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.33B | 2.34B | 58.85% |
| Mar 31, 2025 | 3.98B | 1.84B | 85.65% |
| Mar 31, 2024 | 2.15B | 1.79B | 507.07% |
| Mar 31, 2023 | 353.37M | 211.67M | 149.38% |
| Mar 31, 2022 | 141.70M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Viyash Scientific | 35.75B |
| Unichem Laboratories | 23.08B |
| FDC Limited | 21.90B |
| Morepen Laboratories | 19.51B |
| Sanofi India | 18.05B |
| Procter & Gamble Health | 14.33B |
| Bliss GVS Pharma | 10.05B |
| Gufic Biosciences | 9.81B |